abstract |
FIELD: biotechnology. n SUBSTANCE: CD19-specific antibody in synergistic combination with bendamustine for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia is declared. n EFFECT: invention provides for synergistic antitumor activity of specific CD19 antibodies and of bendamustine that can be used for effective treatment of B-cell malignancies. n 7 cl, 10 dwg, 10 tbl, 3 ex |